January 7, 2019
Adverum Biotechnologies has sufficient cash to fund operations at least through the first half of 2020, to advance Novel Gene Therapy ADVM-022 for Wet AMD in OPTIC Phase 1 clinical trial
Adverum Biotechnologies, a California-based ophthalmology and rare diseases focused biotech company, expects to provide an update on enrollment from the OPTIC phase 1 clinical trial in the first half of 2019, and interim data on the three cohorts from the OPTIC phase 1 clinical trial by the first quarter of 2020, it said in an outlook for 2019.